Targeting escape mutations
in hematological cancers
with first and best in class medicines

Recent News

Recent News

Nov 4, 2024

Lomond Therapeutics Completes Reverse Merger and Closes $44 Million Private Placement

My 28, 2019

Lomond Therapeutics Announces FDA Clearance of IND Application for Phase 1 Study Of Lonitoclax, a Selective BCL2 Inhibitor, for Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grade Lymphomas